Program
BR3409
A development code.
Its studies are mostly in Diabetes Mellitus, Type 2, led by Boryung Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boryung Pharmaceutical | 20 open or running | phase 1since Mar 11, 2025 | Mar 11, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 11, 2025First studies: 2 phase 1 studies in Diabetes Mellitus, Type 2First studyNCT06879158, NCT06879132
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06879158Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Jan 26, 2025 | 50 |
| NCT06879132Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Dec 7, 2024 | 40 |
How it is read
Names in the registry
- “BR3409”, 2 entries
Codes read as this program: BR3409.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.